NCODA shared a post on LinkedIn:
“As treatment options expand, so do opportunities to offer meaningful support.
With cabozantinib’s new indication for neuroendocrine tumors (NETs), we’ve updated our complimentary Treatment Support Kit (TSK) to better reflect patients’ current needs—preserving core resources while introducing the most relevant new tools.
The refreshed kit includes urea-based skin cream to help manage skin-related side effects, replacing the pill container to better align with the treatment experience. The kit continues to include helpful essentials like loperamide, treatment calendars, diarrhea management education, and more.
Explore all kits and order.”